CSI Market
Sign In | Register

Emmaus Life Sciences (EMMA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EMMA Annual Cash Flow →
Quarterly cash flow trends provide additional context on Emmaus Life Sciences's liquidity and ability to support ongoing operations and capital needs.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2019)
3 Months 		(Dec 31 2018) (Sep 30 2018) (Jun 30 2018) (Mar 31 2018)
Operating Activities
Income-14.15
Depreciation & amortization0.02
Amortization of Other Assets5.64
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-1.09
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.54
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Debt Instrument Increase Accrued Interest-
Warrant Exercise Inducement Expense-
Derivative Gain Loss On Derivative Net-
Foreign Exchange Adjustments On Convertible Notes And Notes Payable-0.02
Induced Conversion Of Convertible Debt Expense-
Gain Loss On Warrant Derivative Liabilities0.05
Increase Decrease In Investment Capital Reserve-
Increase Decrease In Contract With Customer Liability0.50
Income taxes0.00
Unrealized Gain (Loss) on Securities0.00
Increase (Decrease) in Accounts Receivable-0.41
Increase (Decrease) in Accounts Payable and Accrued Liabilities2.34
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.08
Other Working Capital-1.07
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities6.46
Discontinued operations0.00
Net Cash flow from Operating Activities-1.28
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.02
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-3.05
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.54
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Due To Dissenters-
Payments For Repurchase Of Common Stock And Warrants-
Proceeds From Conversion Of Notes Payable To Common Stock0.02
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.49
Effect of exchange rate on cash flow0.02
Discontinued operations0.00
Free Cash Flow-1.30
Total Cash Flow-1.77
4 historic quarters locked

Sign in to unlock the full Emmaus Life Sciences cash flow history.

Sign In Create Free Account

About EMMA Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.